ArticleInternational journal of pharmaceutics: X2026
Curcumin-releasing oxidized konjac/GelMA hydrogel for ROS-mediated suppression of postoperative prostate cancer recurrence and metastasis.
Article in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postoperative recurrence remains a major challenge in prostate cancer (PCa) treatment, and insufficient drug concentration at the tumor site represents a critical barrier to effectively suppressing tumor regrowth and lymph node metastasis. To address these limitations, we developed a photo-crosslinkable oxidized konjac glucomannan/gelatin-methacrylate hydrogel (OG@Cur) for localized and sustained delivery of curcumin (Cur) during the postoperative period. This hydrogel forms a porous and adhesive network that enables prolonged curcumin release during biodegradation while simultaneously facilitating hemostasis. Cur released from the hydrogel maintained a high local concentration at the surgical site, thereby enhancing antitumor activity through the induction of intracellular reactive oxygen species accumulation. In a postoperative PCa recurrence model, this localized and sustained delivery strategy significantly suppressed tumor regrowth and reduced lymph node metastasis, while exhibiting good biocompatibility. Overall, this hydrogel system, which continuously releases curcumin, provides an effective localized therapeutic approach for preventing postoperative prostate cancer recurrence and may offer advantages over conventional systemic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.